Loading...
Loading...
Alexza Pharmaceuticals,
Inc.
ALXA announced today that the U.S. Food and Drug Administration
(FDA) approved ADASUVE^® (loxapine) Inhalation Powder 10 mg for the acute
treatment of agitation associated with schizophrenia or bipolar I disorder in
adults. ADASUVE combines Alexza's proprietary Staccato^® delivery system with
the antipsychotic drug, loxapine. The Staccato system is a hand-held inhaler
that delivers a drug aerosol to the deep lung that results in rapid systemic
delivery and absorption of a drug. See below for Important Safety Information
about ADASUVE, including Boxed Warnings.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in